Mechanisms of RBM20 Cardiomyopathy: Insights From Model Systems

Zachery R. GregorichYanghai ZhangTimothy J. KampHenk GranzierWei GuoDepartment of Animal and Dairy Sciences,University of Wisconsin-Madison. (Z.R.G.,Y.Z.,W.G.)Cellular and Molecular Arrhythmia Research Program,University of Wisconsin-Madison. (T.J.K.)Department of Medicine,University of Wisconsin-Madison. (T.J.K.)Cardiovascular Research Center,University of Wisconsin-Madison. (T.J.K.,W.G.)Department of Cellular and Molecular Medicine,The University of Arizona,Tucson (H.G.).

DOI: https://doi.org/10.1161/circgen.123.004355

2024-01-31

Circulation Genomic and Precision Medicine

Abstract:Circulation: Genomic and Precision Medicine, Ahead of Print. RBM20 (RNA-binding motif protein 20) is a vertebrate- and muscle-specific RNA-binding protein that belongs to the serine-arginine-rich family of splicing factors. TheRBM20gene was first identified as a dilated cardiomyopathy–linked gene over a decade ago. Early studies inRbm20knockout rodents implicated disrupted splicing of RBM20 target genes as a causative mechanism. Clinical studies show that pathogenic variants inRBM20are linked to aggressive dilated cardiomyopathy with early onset heart failure and high mortality. Subsequent studies employing pathogenic variant knock-in animal models revealed that variants in a specific portion of the arginine-serine-rich domain in RBM20 not only disrupt splicing but also hinder nucleocytoplasmic transport and lead to the formation of RBM20 biomolecular condensates in the sarcoplasm. Conversely, mice harboring a disease-associated variant in the RRM (RNA recognition motif) do not show evidence of adverse remodeling or exhibit sudden death despite disrupted splicing of RBM20 target genes. Thus, whether disrupted splicing, biomolecular condensates, or both contribute to dilated cardiomyopathy is under debate. Beyond this, additional questions remain, such as whether there is sexual dimorphism in the presentation of RBM20 cardiomyopathy. What are the clinical features of RBM20 cardiomyopathy and why do some individuals develop more severe disease than others? In this review, we summarize the reported observations and discuss potential mechanisms of RBM20 cardiomyopathy derived from studies employing in vivo animal models and in vitro human-induced pluripotent stem cell–derived cardiomyocytes. Potential therapeutic strategies to treat RBM20 cardiomyopathy are also discussed.

genetics & heredity,cardiac & cardiovascular systems